Home » AKORN SIGNS LETTER OF INTENT WITH AZAD PHARMA AG TO DEVELOP AND SUPPLY THREE ANDA INJECTABLE DRUG PRODUCTS
AKORN SIGNS LETTER OF INTENT WITH AZAD PHARMA AG TO DEVELOP AND SUPPLY THREE ANDA INJECTABLE DRUG PRODUCTS
Akorn, Inc. today announced that it has signed a Letter of Intent with Azad Pharma AG, located in Toffen Switzerland, to develop and supply three ANDA injectable drug products for critical care medicine. The Letter of Intent anticipates executing a Definitive Agreement within ninety days upon Terms and Conditions agreeable to both Akorn and Azad.
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051214005621&newsLang=en)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May